Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
It is Health Canada-approved to help people with type 2 diabetes (T2D) manage their blood glucose levels
2037-A DIAGNOSTIC ACCURACY OF VCTE AND 2D-SWE IN BIOPSY-PROVEN NAFLD AND PERFORMANCE OF TWO-STEP APPROACHES TO PREDICT ADVANCED FIBROSIS Madalina-Gabriela Taru 1,2 , Dan-Corneliu Leucuta 2 , Lidia Neamti 2 , Anca Maniu 3 , Vlad Taru 4 , Bobe Petrushev 3 , Ioana Rusu 3 , Cristian Tefas 2,3 , Petra Fischer 2 , Andreea-Ioana Terec 5 , Lucia Maria Procopciuc 2 , Bogdan Procopet 2 , Horia Stefanescu 3 and Monica Lupsor-Platon 2,3 , (1)Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy, (2)Luliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania, (3)Octavian Fodor Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania, (4)Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, (5)Niculae Stncioiu Heart Institute, 400001, Cluj-Napoca, Romania Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose significant challenges to the healthcare system, and the prediction of advanced fibrosis (F3) is a crucial aspect in their management
Some insurance plans may require prior authorization before covering the medication
First, ensure adequate hydration and review recent dietary changes
Service members struggling with weight are nearly 50% more likely to suffer musculoskeletal injuries, which can lead to long-term disability and medical discharge
